Will Star Health, HDFC ERGO, ICICI Lombard, and Niva Bupa cover this?

Each insurer assesses named-patient imports case by case. Some reimburse fully when Darzalex is on their formulary even if not currently stocked, some reimburse a percentage subject to copay, and many require pre-authorisation. We supply the documentation set that allows your insurer to assess the case; the claim itself sits with you or your hospital.

Is the FDA-approved indication recognised by CDSCO?

The CDSCO named-patient pathway exists precisely to permit access when the local registration or stocking lags the FDA label. The application documents the FDA indication, the reference-authority approval, and the local gap; CDSCO review focuses on the clinical justification rather than re-litigating the FDA decision.

My physician is licensed in one emirate / state / province and the hospital is in another. Is that fine?

Any Indian-licensed physician practicing in good standing in the jurisdiction of the dispensing facility has signing authority on the clinical justification letter. The State Medical Council and the CDSCO Zonal Office verifies the active license; the CDSCO application records both the prescribing physician and the dispensing facility.

Can I receive Darzalex at home?

The dispensing facility must be Indian-licensed. The hospital outpatient or specialty pharmacy releases the medicine to you after final verification, and you then administer or self-administer at home where the FDA label permits, after the dispensing pharmacy's training. The cold-chain or controlled-storage handoff ends at the dispensing pharmacy; home storage and any handling protocol are part of your patient onboarding kit.

What about competitors or alternative therapies in the same class?

Choice of therapy depends on the patient's full phenotype, prior therapy, and the prescriber's judgment. Reserve Meds coordinates whichever medicine the physician has prescribed; we do not substitute, advise on substitution, or promote one brand over another.

Indicative drug-only band: USD 3,000 to 5,000 per dose (cycle-dependent frequency). Delivered quote within 24h.Get my quote

Darzalex access in India: the CDSCO named-patient pathway

How patients in the Republic of India legally obtain Darzalex (daratumumab) when the locally registered indication, stocked presentation, or payer coverage does not match what the prescribing physician has written.

Last reviewed 2026-05-12 by Reserve Meds clinical and regulatory team.

Quick orientation

Patients in India access Darzalex (daratumumab) for multiple myeloma in newly diagnosed and relapsed/refractory settings in combination regimens, and light-chain amyloidosis, under the FDA label through the CDSCO named-patient pathway, a Central Drugs Standard Control Organisation-administered mechanism that allows an Indian-licensed physician at a registered facility to import the FDA-labelled product for a specific named patient. This page details the documentation, approval timeline, and real cost in INR.

Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.

Reserved for you.

How Darzalex reaches patients in India

Darzalex (daratumumab IV, FDA-approved 2015; Darzalex Faspro SC, FDA-approved 2020; Janssen, anti-CD38 monoclonal antibody) is partially registered with CDSCO through Janssen's Indian affiliate and appears on the SUGAM database at cdscoonline.gov.in for selected presentations. Where the prescribed presentation, vial strength, FDA-label combination indication (for example D-VRd induction for newly diagnosed transplant-eligible myeloma per the PERSEUS expansion), or the SC Faspro form is not locally stocked, Indian patients access Darzalex via Form 12-A personal-use import under Rules 36 and 36A of the Drugs and Cosmetics Rules 1945; CDSCO issues Form 12-B typically within one to two working days when documentation is complete per cdsco.gov.in/consumer/Drugs-for-Personal-Use. Hospital-led imports for the named patient use CT Form-16 under the New Drugs and Clinical Trials Rules 2019. The Darzalex-specific clinical justification must document myeloma stage (ISS or R-ISS), prior lines of therapy where applicable, intended combination backbone (bortezomib plus lenalidomide plus dexamethasone, or others), infusion-related-reaction premedication plan for IV daratumumab, or the SC dosing schedule for Faspro. Cold-chain handling (2 to 8 degrees Celsius) is documented in the application. CDSCO Form 12-B is single-consignment; oncology cycles re-file per supply window.

Where Darzalex is administered in India

Darzalex IV requires infusion-capable day-care medical oncology or haematology with slow first-infusion protocols and pre-medication; Faspro SC requires ambulatory injection capacity with monitoring. Indian tertiary haematology, oncology, and BMT centres routinely administering daratumumab include the Tata Memorial Hospital Department of Medical Oncology and Adult Haematolymphoid Disease Management Group in Mumbai at tmc.gov.in; All India Institute of Medical Sciences (AIIMS) Department of Medical Oncology and Department of Haematology in New Delhi at aiims.edu; the Christian Medical College (CMC) Vellore Department of Clinical Haematology (a national reference centre for plasma-cell dyscrasias) at clin.cmcvellore.ac.in; the Postgraduate Institute of Medical Education and Research (PGIMER) Chandigarh Department of Internal Medicine and Department of Haematology; the Tata Medical Center Kolkata Adult Haematology Service; Apollo Hospitals Multiple Myeloma and BMT services in Chennai, Hyderabad, and Delhi; Fortis Memorial Research Institute Gurugram; and Medanta The Medicity Department of Haematology and Bone Marrow Transplant. TMC, AIIMS, and CMC Vellore publish department heads and run structured plasma-cell-dyscrasia clinics; they are the most-frequent reference nodes for transplant-eligible newly-diagnosed myeloma where Darzalex-containing induction is standard.

What Darzalex costs in India

The US reference WAC for Darzalex IV is approximately USD 6,500 to USD 8,000 per 400 mg vial; Faspro 1,800 mg SC is approximately USD 10,500 to USD 12,000 per dose per Drugs@FDA at accessdata.fda.gov/scripts/cder/daf. Standard weekly-then-biweekly-then-monthly IV induction drives USD 15,000 to USD 25,000 monthly during induction. Janssen India publishes a local MRP for the registered Darzalex presentation through approved distribution; reporting from Indian myeloma patient organisations and pharmacy-distributor channels has historically placed the locally-procured INR price for a 400 mg vial in the range of INR 200,000 to INR 250,000 depending on stock window and supply, though this is supply-window-dependent and is not a stable NPPA ceiling. NPPA's database at nppaindia.nic.in does not list daratumumab under a Drug Price Control Order ceiling as of 2026-05-31. Where the prescribed Faspro SC form is needed but only the IV is locally stocked, Form 12-A import is the bridge. Price snapshot: 2026-05-31. Cost layers: cold-chain international logistics (mid four-figure USD), CDSCO permit fees (nominal), hospital infusion-administration and premedication fees, and Reserve Meds concierge fee itemised separately.

Funding and access barriers for Darzalex in India

Multiple myeloma in India has an estimated age-standardised incidence approximately 1.2 to 1.5 per 100,000 per year. Public-sector funding: Rashtriya Arogya Nidhi (RAN) at mohfw.gov.in RAN page provides financial assistance up to a defined ceiling for BPL patients treated at designated government super-specialty hospitals (AIIMS, Tata Memorial, PGIMER, etc.); the Health Minister's Cancer Patient Fund (HMCPF) sub-fund earmarks resources for cancer at 27 designated Regional Cancer Centres. Ayushman Bharat PM-JAY covers selected myeloma admission packages up to INR 5 lakh per family per year; daratumumab is not consistently a separate-list item. State schemes (Tamil Nadu CMCHIS, Kerala KASP, Karnataka Ayushman Bharat-Arogya Karnataka, Andhra Aarogyasri) include selected myeloma packages with state-specific drug lists. Private insurance: standalone health insurers (Star Health, Niva Bupa, HDFC ERGO Health, Care Health, ManipalCigna) and general insurers (New India Assurance, ICICI Lombard, Bajaj Allianz, Tata AIG) increasingly cover daratumumab on higher-tier individual and corporate group policies subject to step-therapy and prior-authorisation criteria; IRDAI does not publish a national standard for NPP-imported drug coverage. Janssen India compassionate-access programmes have historically been a meaningful pathway for myeloma patients; eligibility is means-tested. The Form 12-B cold-chain import experience is operationally well-established for biologics into the major Indian air-cargo hubs.

Recent regulatory and access news for Darzalex

FDA approved (July 2024) Darzalex Faspro plus bortezomib, lenalidomide, and dexamethasone (D-VRd) for newly diagnosed multiple myeloma in transplant-eligible adults based on the PERSEUS trial, establishing a daratumumab-containing quadruplet as the new induction standard; the approval letter is at accessdata.fda.gov/scripts/cder/daf. FDA expanded the Faspro label (August 2024) to high-risk smouldering multiple myeloma. CDSCO Notifications at cdsco.gov.in/Notifications has issued routine periodic notifications on biologic-product registration timelines but no Darzalex-specific bulletin over the last 12 months as of 2026-05-31. NPPA continues quarterly Drug Price Control Order ceiling updates; no daratumumab ceiling has been added.

Where Reserve Meds fits in Darzalex cases

Reserve Meds is a US-based concierge coordinator. We do not replace your treating physician, we do not replace CDSCO, and we do not replace your dispensing pharmacy. For Darzalex specifically, we orchestrate the US-side sourcing through a DSCSA-compliant specialty channel, build the documentation packet your physician submits, coordinate validated logistics (cold-chain with continuous temperature logging where the FDA label requires it) into India, and assign a single named coordinator through the case. Standard named-patient coordination under our specialty playbook applies. Presentation selection, dose-band confirmation, and patient onboarding for self-administration where applicable are the recurring operational fundamentals we expect for this drug.

Operationally, a typical Darzalex case runs across four parallel tracks. The clinical track is the physician's: justification letter, dosing plan, monitoring schedule, and the next patient-facing follow-up. The regulatory track is the CDSCO application packaged by the importer; we provide the documentation template, the dispensing facility license check, and the chain-of-custody attestation. The logistics track is the US-side sourcing and the validated international shipment with continuous temperature logging and customs broker coordination. The patient-experience track is the named coordinator who keeps everyone aligned on dates, addresses dispensing-pharmacy questions, and confirms the medicine has been received and stored correctly. The four tracks are run in parallel rather than in series; that is the operational difference between a 3-week and a 9-week case.

Indian myeloma programmes at Tata Memorial, CMC Vellore, and Apollo handle anti-CD38 therapy with structured infusion monitoring; Rule 36 personal import or Form 12A institutional use applies.

Next step

If your Indian physician has prescribed Darzalex and you are weighing the cross-border route, the next step is a short intake. We confirm eligibility within 24 to 48 hours and send a documentation kit to your physician.

Start your Darzalex case Or message us on WhatsApp